See more : Astro Malaysia Holdings Berhad (6399.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Nu Skin Enterprises, Inc. (NUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nu Skin Enterprises, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- Management Solutions co.,Ltd. (7033.T) Income Statement Analysis – Financial Results
- Park Lawn Corporation (PLC.TO) Income Statement Analysis – Financial Results
- Royal India Corporation Limited (ROYALIND.BO) Income Statement Analysis – Financial Results
- Shivalik Bimetal Controls Limited (SHBCLQ.BO) Income Statement Analysis – Financial Results
- American Green, Inc. (ERBB) Income Statement Analysis – Financial Results
Nu Skin Enterprises, Inc. (NUS)
About Nu Skin Enterprises, Inc.
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.97B | 2.23B | 2.70B | 2.58B | 2.42B | 2.68B | 2.28B | 2.21B | 2.25B | 2.57B | 3.18B | 2.17B | 1.74B | 1.54B | 1.33B | 1.25B | 1.16B | 1.12B | 1.18B | 1.14B | 986.46M | 964.07M | 885.62M | 879.76M | 894.20M | 913.50M | 890.50M | 678.60M | 358.60M |
| Cost of Revenue | 611.85M | 630.92M | 675.22M | 658.03M | 581.42M | 634.14M | 502.08M | 500.46M | 489.51M | 478.43M | 505.81M | 353.15M | 322.62M | 272.43M | 243.65M | 228.60M | 209.28M | 195.20M | 206.16M | 191.21M | 176.55M | 190.87M | 178.08M | 111.74M | 118.50M | 169.10M | 224.40M | 187.80M | 94.60M |
| Gross Profit | 1.36B | 1.59B | 2.02B | 1.92B | 1.84B | 2.04B | 1.78B | 1.71B | 1.76B | 2.09B | 2.67B | 1.82B | 1.42B | 1.26B | 1.09B | 1.02B | 948.38M | 920.21M | 974.77M | 946.65M | 809.91M | 773.20M | 707.54M | 768.02M | 775.70M | 744.40M | 666.10M | 490.80M | 264.00M |
| Gross Profit Ratio | 68.93% | 71.65% | 74.95% | 74.51% | 75.98% | 76.33% | 77.97% | 77.33% | 78.22% | 81.38% | 84.08% | 83.72% | 81.50% | 82.28% | 81.70% | 81.68% | 81.92% | 82.50% | 82.54% | 83.20% | 82.10% | 80.20% | 79.89% | 87.30% | 86.75% | 81.49% | 74.80% | 72.33% | 73.62% |
| Research & Development | 22.60M | 23.30M | 27.20M | 23.30M | 30.10M | 23.00M | 22.00M | 24.30M | 20.10M | 18.90M | 18.00M | 14.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 546.86M | 555.77M | 666.40M | 646.85M | 615.97M | 662.30M | 564.51M | 554.15M | 561.46M | 622.30M | 640.03M | 505.45M | 436.18M | 401.42M | 378.34M | 364.25M | 361.24M | 353.41M | 354.22M | 333.26M | 289.93M | 0.00 | 636.06M | 640.00M | 612.80M | 533.60M | 503.60M | 0.00 | 0.00 |
| Selling & Marketing | 742.37M | 879.63M | 1.07B | 1.02B | 955.60M | 1.07B | 938.02M | 922.08M | 951.37M | 1.12B | 1.48B | 970.22M | 751.45M | 646.35M | 550.64M | 529.37M | 496.45M | 480.14M | 497.42M | 487.63M | 407.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.29B | 1.44B | 1.73B | 1.67B | 1.57B | 1.73B | 1.50B | 1.48B | 1.51B | 1.74B | 2.12B | 1.48B | 1.19B | 1.05B | 928.97M | 893.62M | 857.70M | 833.55M | 851.64M | 820.89M | 697.01M | 667.39M | 636.06M | 640.00M | 612.80M | 533.60M | 503.60M | 357.10M | 203.20M |
| Other Expenses | -21.69M | -21.88M | -1.53M | -1.33M | -12.25M | -21.19M | -8.92M | -18.27M | -32.74M | -53.68M | 2.83M | 4.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.84M | 0.00 | 0.00 | 0.00 | 191.29M | 169.37M | 37.60M | 33.20M | 41.00M | 24.00M | 5.40M | 2.00M |
| Operating Expenses | 1.29B | 1.44B | 1.73B | 1.67B | 1.57B | 1.73B | 1.50B | 1.48B | 1.51B | 1.74B | 2.12B | 1.48B | 1.19B | 1.05B | 928.97M | 893.62M | 857.70M | 854.39M | 851.64M | 820.89M | 697.01M | 667.39M | 636.06M | 677.61M | 646.00M | 574.60M | 527.60M | 362.50M | 205.20M |
| Cost & Expenses | 1.90B | 2.07B | 2.41B | 2.32B | 2.15B | 2.37B | 2.00B | 1.98B | 2.00B | 2.22B | 2.62B | 1.83B | 1.51B | 1.32B | 1.17B | 1.12B | 1.07B | 1.05B | 1.06B | 1.01B | 873.56M | 858.26M | 814.14M | 789.35M | 764.50M | 743.70M | 752.00M | 550.30M | 299.80M |
| Interest Income | 0.00 | 10.38M | 11.16M | 13.12M | 19.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 21.88M | 11.00M | 13.10M | 19.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.80M | 6.90M | 7.80M | 7.80M | 8.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 69.60M | 72.51M | 125.02M | 120.15M | 121.11M | 83.00M | 71.56M | 72.40M | 71.37M | 54.92M | 34.92M | 33.41M | 32.85M | 29.62M | 28.56M | 30.39M | 32.97M | 29.13M | 31.37M | 28.66M | 23.08M | 21.60M | 32.43M | 37.60M | 33.20M | 41.00M | 24.00M | 5.40M | 2.00M |
| EBITDA | 137.66M | 231.85M | 368.48M | 331.56M | 267.43M | 394.55M | 346.05M | 303.50M | 316.07M | 407.11M | 589.04M | 374.26M | 266.59M | 246.68M | 176.58M | 138.85M | 109.75M | 86.91M | 154.91M | 125.76M | 135.98M | 105.81M | 71.48M | 128.02M | 162.90M | 210.80M | 212.20M | 149.20M | 60.80M |
| EBITDA Ratio | 6.99% | 9.34% | 12.53% | 12.84% | 11.05% | 14.27% | 12.04% | 10.47% | 10.89% | 13.71% | 17.44% | 15.71% | 13.80% | 14.73% | 13.20% | 12.04% | 12.60% | 11.56% | 13.44% | 13.89% | 14.31% | 13.52% | 10.79% | 13.87% | 18.37% | 23.08% | 17.05% | 19.29% | 16.82% |
| Operating Income | 48.27M | 110.85M | 233.99M | 257.56M | 190.78M | 240.86M | 274.48M | 231.10M | 244.70M | 352.19M | 554.11M | 340.84M | 233.74M | 217.06M | 147.71M | 125.43M | 70.91M | 54.70M | 123.12M | 125.76M | 107.31M | 105.81M | 71.48M | 90.41M | 129.70M | 169.80M | 138.50M | 128.30M | 58.80M |
| Operating Income Ratio | 2.45% | 4.98% | 8.68% | 9.98% | 7.88% | 8.99% | 12.04% | 10.47% | 10.89% | 13.71% | 17.44% | 15.71% | 13.40% | 14.12% | 11.10% | 10.05% | 6.13% | 4.90% | 10.43% | 11.05% | 10.88% | 10.98% | 8.07% | 10.28% | 14.50% | 18.59% | 15.55% | 18.91% | 16.40% |
| Total Other Income/Expenses | -21.69M | -21.88M | -1.53M | -1.33M | -12.25M | -21.19M | -8.92M | -18.27M | -32.74M | -53.68M | 2.83M | 4.40M | -6.97M | -9.45M | -6.59M | -24.78M | -2.44M | -2.03M | -4.17M | -3.62M | 432.00K | -2.89M | 8.38M | 5.99M | -1.30M | -3.10M | -6.00M | -2.90M | 500.00K |
| Income Before Tax | 26.58M | 88.97M | 232.46M | 256.23M | 255.17M | 219.67M | 265.57M | 212.84M | 211.96M | 298.51M | 556.94M | 345.24M | 226.77M | 207.61M | 141.12M | 100.65M | 68.48M | 52.68M | 118.95M | 122.14M | 107.74M | 102.93M | 79.86M | 96.41M | 128.40M | 166.70M | 149.30M | 131.20M | 59.30M |
| Income Before Tax Ratio | 1.35% | 4.00% | 8.62% | 9.92% | 10.54% | 8.20% | 11.65% | 9.64% | 9.43% | 11.62% | 17.53% | 15.91% | 13.00% | 13.51% | 10.60% | 8.07% | 5.92% | 4.72% | 10.07% | 10.73% | 10.92% | 10.68% | 9.02% | 10.96% | 14.36% | 18.25% | 16.77% | 19.33% | 16.54% |
| Income Tax Expense | 17.98M | -15.81M | 85.19M | 64.88M | 81.62M | 97.78M | 136.13M | 69.75M | 78.91M | 109.33M | 192.05M | 123.60M | 73.44M | 71.56M | 51.28M | 35.31M | 24.61M | 19.86M | 44.92M | 44.47M | 39.86M | 38.08M | 29.55M | 34.71M | 41.70M | 62.80M | 55.70M | 49.50M | 19.10M |
| Net Income | 8.60M | 104.78M | 147.27M | 191.36M | 173.55M | 121.89M | 129.44M | 143.09M | 133.05M | 189.18M | 364.89M | 221.65M | 153.33M | 136.05M | 89.85M | 65.35M | 43.87M | 32.82M | 74.03M | 77.67M | 67.88M | 64.84M | 50.31M | 61.70M | 86.70M | 103.90M | 93.60M | 81.70M | 40.20M |
| Net Income Ratio | 0.44% | 4.71% | 5.46% | 7.41% | 7.17% | 4.55% | 5.68% | 6.48% | 5.92% | 7.36% | 11.49% | 10.22% | 8.79% | 8.85% | 6.75% | 5.24% | 3.79% | 2.94% | 6.27% | 6.83% | 6.88% | 6.73% | 5.68% | 7.01% | 9.70% | 11.37% | 10.51% | 12.04% | 11.21% |
| EPS | 0.17 | 2.10 | 2.93 | 3.66 | 3.13 | 2.21 | 2.45 | 2.58 | 2.29 | 3.20 | 6.23 | 3.66 | 2.47 | 2.18 | 1.42 | 1.03 | 0.68 | 0.47 | 1.06 | 1.10 | 0.86 | 0.79 | 0.60 | 0.72 | 1.00 | 1.22 | 1.42 | 1.07 | 0.51 |
| EPS Diluted | 0.17 | 2.07 | 2.86 | 3.63 | 3.10 | 2.16 | 2.36 | 2.55 | 2.25 | 3.11 | 5.94 | 3.52 | 2.38 | 2.11 | 1.40 | 1.02 | 0.67 | 0.47 | 1.04 | 1.07 | 0.85 | 0.78 | 0.60 | 0.72 | 0.99 | 1.19 | 1.36 | 1.02 | 0.50 |
| Weighted Avg Shares Out | 49.71M | 50.00M | 50.19M | 52.30M | 55.52M | 55.17M | 52.81M | 55.41M | 58.00M | 59.07M | 58.61M | 60.60M | 62.07M | 62.37M | 63.33M | 63.51M | 64.78M | 69.42M | 70.05M | 70.73M | 78.64M | 81.73M | 83.47M | 85.40M | 87.08M | 84.89M | 83.33M | 79.16M | 78.82M |
| Weighted Avg Shares Out (Dil) | 49.86M | 50.53M | 51.43M | 52.77M | 55.93M | 56.48M | 54.85M | 56.10M | 59.06M | 60.89M | 61.45M | 63.03M | 64.55M | 64.55M | 64.30M | 64.13M | 65.58M | 70.51M | 71.36M | 72.63M | 79.54M | 83.13M | 83.92M | 85.64M | 87.89M | 87.02M | 87.31M | 83.04M | 80.40M |
Vanity Stocks Nu-Skin (NUS), ULTA, HIMS Offer Upside Potential
With such a great start to the holiday week, we could not help but gloat a little about the stocks I have mentioned related to the diet drugs, or what I call the “vanity” trade.
Nu Skin: New Products And Ongoing Digital Transformation Imply Undervaluation
Nu Skin Enterprises, Inc. demonstrates a tested business model with long-term free cash flow generation, supported by acquisitions, new products, and digital transformation. Despite recent earnings disappointments, optimistic 2025-2026 EPS growth projections and multiple revenue catalysts suggest significant upside potential...
Nu Skin Q3 Earnings & Sales Miss Estimates, 2024 Guidance Cut
NUS' Q3 results show lower earnings and net sales amid macroeconomic pressures and challenges in the direct selling industry. Management lowers 2024 view.
Nu Skin Enterprises, Inc. (NUS) Q3 2024 Earnings Call Transcript
Nu Skin Enterprises, Inc. (NYSE:NUS ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Scott Pond - Vice President-Investor Relations Ryan Napierski - President and Chief Executive Officer James Thomas - Chief Financial Officer Conference...
Nu Skin Enterprises (NUS) Lags Q3 Earnings and Revenue Estimates
Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.56 per share a year ago.
4 Cosmetics Stocks Worth Watching Despite Industry Challenges
The Zacks Cosmetics industry is navigating a tough shopping environment. Nevertheless, COTY, Helen of Troy, European Wax Center and Nu Skin are leveraging innovations.
Nu Skin's Q3 Earnings Coming Up: Here's What You Should Know
NUS' Q3 results are likely to reflect the impacts of macroeconomic hurdles on consumer spending and customer acquisition.
Later Drives Full-Funnel Influencer Marketing Impact with New Affiliate Campaign Capabilities, Leveraging a Strategic Partnership with Mavely
Today's announcement continues the company's vision of driving predictable outcomes for social commerce. BOSTON , Oct. 22, 2024 /PRNewswire/ -- Later , a leading social media and influencer marketing partner for Fortune 5000 brands, partners with Mavely , the Everyday...
FPT and National University of Singapore Join Forces in Driving AI Innovation and Fostering Talent Development
SINGAPORE--(BUSINESS WIRE)--The National University of Singapore's School of Computing (NUS Computing) has entered into a partnership with FPT, a leading global technology corporation based in Vietnam, to advance the field of artificial intelligence (AI). This collaboration plans a joint investment...
Nu Skin: Betting On A Potential Comeback
Nu Skin Enterprises is at a potential inflection point with seemingly stabilized revenue. Management's restructuring and innovative product focus, particularly through the Rhyz business, show promise for a turnaround and long-term growth. A strong balance sheet and steady cash flow...
Source: https://incomestatements.info
Category: Stock Reports